Literature DB >> 9290401

Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration.

F Cecchi1, A Montereggi, I Olivotto, P Marconi, A Dolara, B J Maron.   

Abstract

OBJECTIVE: To assess the relation between P wave duration and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy (HCM).
DESIGN: High resolution signal averaged electrocardiography was used in 110 patients with HCM to determine whether patients at risk for paroxysmal atrial fibrillation could be detected during sinus rhythm by measuring P wave duration. Filtered P wave duration was measured manually, over an average of 300 beats per patient.
RESULTS: During follow up, 18 patients (16%) had at least one one clinical episode of paroxysmal atrial fibrillation, including four patients whose initial episode followed the signal averaged electrocardiogram. The 18 patients with overt atrial fibrillation had greater P wave duration than the 69 patients who did not develop atrial fibrillation: 150 (SD 20) v 126 (14) ms; P < 0.001. Another 23 patients without clinically evident atrial fibrillation had prolonged bursts of the arrhythmia on Holter recording, and showed a P wave duration (138 (15) ms) intermediate between patients with and without clinical atrial fibrillation. In assessing risk for atrial fibrillation, P wave duration > or = 140 ms was associated with sensitivity, specificity, and positive predictive accuracy values of 56%, 83%, and 66%. Multivariate analysis showed that duration of the P wave was the only independent variable associated with occurrence of atrial fibrillation; if P wave duration > or = 140 ms was combined with left atrial enlargement > 40 mm, the specificity and positive predictive accuracy for atrial fibrillation increased to 93% and 78%.
CONCLUSIONS: Measurement of P wave duration in sinus rhythm by high resolution signal averaged electrocardiography may be a useful non-invasive clinical tool for identifying patients with HCM likely to develop electrical instability and atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290401      PMCID: PMC484863          DOI: 10.1136/hrt.78.1.44

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  21 in total

1.  Relation between echocardiographically determined left atrial size and atrial fibrillation.

Authors:  W L Henry; J Morganroth; A S Pearlman; C E Clark; D R Redwood; S B Itscoitz; S E Epstein
Journal:  Circulation       Date:  1976-02       Impact factor: 29.690

2.  Hypertrophic cardiomyopathy: a discussion of nomenclature.

Authors:  B J Maron; S E Epstein
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

3.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.

Authors:  F Cecchi; I Olivotto; A Montereggi; G Santoro; A Dolara; B J Maron
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

4.  Signal-averaged P wave in patients with Wolff-Parkinson-White syndrome after successful radiofrequency catheter ablation.

Authors:  I G Maia; F E Cruz Filho; M L Fagundes; S H Boghossian; L Vanheusden; R M Sa; P A Alves
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

5.  Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction.

Authors:  M B Simson
Journal:  Circulation       Date:  1981-08       Impact factor: 29.690

6.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients.

Authors:  B J Maron; J S Gottdiener; S E Epstein
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

7.  Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis.

Authors:  D L Glancy; K P O'Brien; H K Gold; S E Epstein
Journal:  Br Heart J       Date:  1970-09

Review 8.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.

Authors:  E D Wigle; Z Sasson; M A Henderson; T D Ruddy; J Fulop; H Rakowski; W G Williams
Journal:  Prog Cardiovasc Dis       Date:  1985 Jul-Aug       Impact factor: 8.194

9.  Relation between the widening of the fragmented atrial activity zone and atrial fibrillation.

Authors:  T Ohe; M Matsuhisa; S Kamakura; J Yamada; I Sato; K Nakajima; K Shimomura
Journal:  Am J Cardiol       Date:  1983-12-01       Impact factor: 2.778

10.  Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy.

Authors:  W J Stafford; R G Trohman; M Bilsker; L Zaman; A Castellanos; R J Myerburg
Journal:  J Am Coll Cardiol       Date:  1986-03       Impact factor: 24.094

View more
  10 in total

1.  Circadian behavior of P-wave duration, P-wave area, and PR interval in healthy subjects.

Authors:  P E Dilaveris; P Färbom; V Batchvarov; A Ghuran; M Malik
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

2.  Filtered signal-averaged P-wave duration during pneumoperitoneum in patients undergoing laparoscopic cholecystectomy: A reflection of pathophysiological cardiac changes.

Authors:  Amitai Bickel; Michael Marinovski; Alexander Shturman; Nathan Roguin; Igor Waksman; Arie Eitan
Journal:  Surg Endosc       Date:  2007-12-11       Impact factor: 4.584

Review 3.  Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy.

Authors:  I Olivotto; B J Maron; F Cecchi
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 4.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

5.  Variable interatrial conduction illustrated in a hypertrophic cardiomyopathy population.

Authors:  Fredrik Holmqvist; Pyotr G Platonov; Jonas Carlson; Rasmus Havmöller; Johan E P Waktare; William J McKenna; S Bertil Olsson; Carl J Meurling
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-07       Impact factor: 1.468

Review 6.  Predictors of Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy.

Authors:  Kamil Tuluce; Selcen Yakar Tuluce
Journal:  J Atr Fibrillation       Date:  2015-02-28

7.  CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Authors:  Theano Papavassiliu; Tjeerd Germans; Stephan Flüchter; Christina Doesch; Anton Suriyakamar; Dariusch Haghi; Tim Süselbeck; Christian Wolpert; Dietmar Dinter; Stefan O Schoenberg; Albert C van Rossum; Martin Borggrefe
Journal:  J Cardiovasc Magn Reson       Date:  2009-09-09       Impact factor: 5.364

8.  Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY).

Authors:  Marion Hourqueig; Guillaume Bouzille; Albert Hagège; Erwan Donal; Mariana Mirabel; Olivier Huttin; Thibaud Damy; Fabien Labombarda; Jean-Christophe Eicher; Philippe Charron; Gilbert Habib; Patricia Réant
Journal:  Clin Res Cardiol       Date:  2021-05-27       Impact factor: 5.460

Review 9.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

10.  Relation of atrial electromechanical delay to P-wave dispersion on surface ECG using vector velocity imaging in patients with hypertrophic cardiomyopathy.

Authors:  Hala Mahfouz Badran; Ghada Soltan; Eslam Eltahan; Magdi H Yacoub; Naglaa Faheem
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-09-24       Impact factor: 1.468

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.